These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23025017)

  • 41. [Cardiovascular adverse effects of cytostatic agents].
    Semb KA; Jakobsen E
    Tidsskr Nor Laegeforen; 2003 Jan; 123(1):44-5. PubMed ID: 12600150
    [No Abstract]   [Full Text] [Related]  

  • 42. [Cardiac complications of chemotherapy and radiotherapy].
    Olive D
    Arch Fr Pediatr; 1981 May; 38(5):379-84. PubMed ID: 7020629
    [No Abstract]   [Full Text] [Related]  

  • 43. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
    Semiglazov VF
    Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
    [No Abstract]   [Full Text] [Related]  

  • 44. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. StatBite: Current ESA usage among cancer patients.
    J Natl Cancer Inst; 2010 Dec; 102(23):1749. PubMed ID: 21088281
    [No Abstract]   [Full Text] [Related]  

  • 46. [The cardiotoxicity of anthracyclines administered in childhood].
    Iarussi D; Indolfi P; Ratti G; Martiniello AR; Iacono A
    G Ital Cardiol; 1998 Dec; 28(12):1431-40. PubMed ID: 9887400
    [No Abstract]   [Full Text] [Related]  

  • 47. [Methods of development of recommendations for clinical practice (RCP) and of setting-up of a platform cancer heart vessels (PTF-CHV) in the inter3C Vaucluse-Arles].
    Debourdeau P; Meuleman C; Dufaitre G; Laroche JP; Slama B; Chebrek S; Aboukhoudir F; Mège A; Dotigny R; Serin D
    Bull Cancer; 2015 Nov; 102(11):932-9. PubMed ID: 26386678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Current state of chemotherapy of tumor diseases].
    Eckhardt S
    Orv Hetil; 1973 Dec; 49(9):2941-8. PubMed ID: 4585543
    [No Abstract]   [Full Text] [Related]  

  • 49. Early cardiotoxicity induced by treatment of hematologic malignancies and the risk-factors of its manifestation.
    Chaladze T; Megreladze I; Zodelava M
    Georgian Med News; 2005 Dec; (129):117-9. PubMed ID: 16444049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges of evaluating the cardiac effects of anticancer agents.
    Bates SE; Rosing DR; Fojo T; Piekarz RL
    Clin Cancer Res; 2006 Jul; 12(13):3871-4. PubMed ID: 16818679
    [No Abstract]   [Full Text] [Related]  

  • 51. Is it possible to use anthracyclines in patients older than 70 years? Contra.
    Del Mastro L; Maggi E; Catzeddu T; Hazini A; Bell C
    Tumori; 2002; 88(1 Suppl 1):S136-7. PubMed ID: 11989908
    [No Abstract]   [Full Text] [Related]  

  • 52. Anthracyclines.
    Gianni L; Grasselli G; Cresta S; Locatelli A; Viganò L; Minotti G
    Cancer Chemother Biol Response Modif; 2003; 21():29-40. PubMed ID: 15338739
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA approves extra safe chemotherapy drug.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):618-9. PubMed ID: 12503201
    [No Abstract]   [Full Text] [Related]  

  • 54. Preliminary clinical trial of Abbott antibiotic A-6413 (NSC-51954).
    Brindley CO; Greenier HJ
    Cancer Chemother Rep; 1966 Dec; 50(9):667-9. PubMed ID: 5342895
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?
    Veccia A; Maines F; Caffo O
    Nat Rev Urol; 2017 Sep; 14(9):1. PubMed ID: 28786420
    [No Abstract]   [Full Text] [Related]  

  • 56. Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?
    Shah SIA; Wilson HCP; Abel PD
    Nat Rev Urol; 2017 Sep; 14(9):1. PubMed ID: 28786419
    [No Abstract]   [Full Text] [Related]  

  • 57. "First, do no harm": chemotherapy or healthy heart?
    Dimos AK; Stougiannos PN; Trikas AG
    Hellenic J Cardiol; 2012 Mar; 53(2):127-36. PubMed ID: 22484778
    [No Abstract]   [Full Text] [Related]  

  • 58. Assessing cardiac safety in oncology drug development.
    Seltzer JH; Gintant G; Amiri-Kordestani L; Singer J; Koplowitz LP; Moslehi JJ; Barac A; Yu AF
    Am Heart J; 2019 Aug; 214():125-133. PubMed ID: 31202099
    [No Abstract]   [Full Text] [Related]  

  • 59. [2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity].
    Bönner F; Fenk R; Kochanek M; Pfister R
    Dtsch Med Wochenschr; 2017 Dec; 142(24):1826-1830. PubMed ID: 29207427
    [No Abstract]   [Full Text] [Related]  

  • 60. [Toxic effect of antitumor therapy on the cardiovascular system].
    Vershinina SF; Gershanovich ML; Makhnova EV; Stukov AN; Tarasenkova AA; Chernolikhov OO
    Vopr Onkol; 2010; 56(2):234-9. PubMed ID: 20552904
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.